PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) traded down 3.7% during mid-day trading on Friday . The stock traded as low as $1.04 and last traded at $1.04. 54,559 shares traded hands during trading, a decline of 78% from the average session volume of 252,493 shares. The stock had previously closed at $1.08.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of PMV Pharmaceuticals in a report on Thursday, March 20th.
View Our Latest Research Report on PMV Pharmaceuticals
PMV Pharmaceuticals Stock Performance
The stock has a 50 day moving average of $1.15 and a 200-day moving average of $1.40. The firm has a market capitalization of $51.93 million, a P/E ratio of -1.00 and a beta of 1.49.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.08). As a group, sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.
Institutional Trading of PMV Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. BML Capital Management LLC boosted its stake in PMV Pharmaceuticals by 105.3% during the fourth quarter. BML Capital Management LLC now owns 3,466,684 shares of the company's stock valued at $5,235,000 after buying an additional 1,777,912 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of PMV Pharmaceuticals during the 4th quarter worth approximately $809,000. Peapod Lane Capital LLC acquired a new position in shares of PMV Pharmaceuticals in the 4th quarter valued at $673,000. Aldebaran Capital LLC lifted its position in PMV Pharmaceuticals by 14.6% during the 4th quarter. Aldebaran Capital LLC now owns 502,190 shares of the company's stock worth $758,000 after buying an additional 63,938 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in PMV Pharmaceuticals by 44.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock valued at $305,000 after buying an additional 62,200 shares during the last quarter. Institutional investors and hedge funds own 90.20% of the company's stock.
PMV Pharmaceuticals Company Profile
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Featured Articles
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
